ENLVEnlivex Therapeutics Ltd.

Nasdaq enlivex.com


$ 1.54 $ -0.03 (-1.9 %)    

Wednesday, 08-May-2024 14:16:18 EDT
QQQ $ 441.16 $ 0.70 (0.16 %)
DIA $ 392.76 $ 2.64 (0.68 %)
SPY $ 519.33 $ 1.89 (0.37 %)
TLT $ 90.38 $ 0.37 (0.41 %)
GLD $ 215.88 $ 1.17 (0.54 %)
$ 1.55
$ 1.56
$ 0.00 x 0
$ 0.00 x 0
$ 1.54 - $ 1.56
$ 1.15 - $ 4.59
47,525
na
28.83M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-enlivex-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7...

 enlivex-announces-dosing-of-first-two-patients-in-its-randomized-controlled-phase-iii-trial-evaluating-allocetra-in-patients-with-knee-osteoarthritis

 Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")))), a clinical-stage macrophage reprogramming immunotherapy com...

 tesla-to-180-here-are-10-top-analyst-forecasts-for-friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-enlivex-therapeutics-lowers-price-target-to-7

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and lowers the pr...

 nasdaq-jumps-250-points-crude-oil-down-1

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The D...

 why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

 dow-dips-100-points-carmax-earnings-miss-views

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday.

 nasdaq-gains-over-50-points-us-producer-prices-increase-in-march

U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the D...

 enlivex-announces-topline-results-of-its-phase-ii-trial-evaluating-allocetra-in-patients-with-sepsis

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the saf...

 enlivex-announces-issuance-of-new-us-patent-number-us-11883429-covering-allocetra-cells-and-their-manufacturing-method

Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the "Company")))), a clinical-stage macrophage reprogramming immunotherapy com...

 enlivex-receives-imoh-authorization-for-initiation-of-multi-country-randomized-controlled-phase-iii-trial-evaluating-allocetra-in-up-to-160-patients-with-moderate-to-severe-knee-osteoarthritis

Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthri...

 why-rayzebio-shares-are-trading-higher-by-100-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acqui...

 why-aar-shares-are-trading-lower-by-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

 enlivex-therapeutics--announced-that-the-company-completed-enrollment-of-all-120-patients-in-its-phase-ii-trial-of-allocetra-in-patients-with-sepsis

Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis studyTopline ...

 why-fortinet-shares-are-trading-lower-by-around-17-here-are-other-stocks-moving-in-fridays-mid-day-session

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

 hc-wainwright--co-maintains-buy-on-enlivex-therapeutics-lowers-price-target-to-12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and lowers the pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION